Lazard Asset Management LLC Has $111.77 Million Stock Position in Kenvue Inc. $KVUE

by · The Markets Daily

Lazard Asset Management LLC increased its holdings in Kenvue Inc. (NYSE:KVUE – Free Report) by 95.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,340,408 shares of the company’s stock after acquiring an additional 2,601,440 shares during the period. Lazard Asset Management LLC’s holdings in Kenvue were worth $111,772,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Renaissance Capital LLC grew its stake in shares of Kenvue by 8.3% during the 2nd quarter. Renaissance Capital LLC now owns 629,177 shares of the company’s stock worth $13,169,000 after acquiring an additional 48,267 shares during the period. Farther Finance Advisors LLC raised its stake in Kenvue by 80.7% in the 2nd quarter. Farther Finance Advisors LLC now owns 36,196 shares of the company’s stock valued at $758,000 after acquiring an additional 16,164 shares during the period. Arlington Partners LLC purchased a new stake in Kenvue during the second quarter valued at about $2,110,000. AG2R LA Mondiale Gestion D Actifs bought a new position in Kenvue during the first quarter worth about $1,725,000. Finally, Cornell Pochily Investment Advisors Inc. boosted its position in Kenvue by 144.6% during the second quarter. Cornell Pochily Investment Advisors Inc. now owns 33,173 shares of the company’s stock worth $694,000 after purchasing an additional 19,609 shares during the period. Institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $17.32 on Friday. The firm has a fifty day moving average price of $16.20 and a two-hundred day moving average price of $19.12. The company has a market cap of $33.18 billion, a price-to-earnings ratio of 23.09 and a beta of 0.60. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.69. Kenvue Inc. has a one year low of $14.02 and a one year high of $25.17.

Kenvue (NYSE:KVUE – Get Free Report) last issued its quarterly earnings data on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. The company had revenue of $3.76 billion for the quarter, compared to the consensus estimate of $3.83 billion. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The firm’s revenue was down 3.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.28 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, November 26th. Shareholders of record on Wednesday, November 12th were issued a $0.2075 dividend. The ex-dividend date of this dividend was Wednesday, November 12th. This represents a $0.83 annualized dividend and a dividend yield of 4.8%. Kenvue’s dividend payout ratio (DPR) is presently 110.67%.

Analyst Ratings Changes

KVUE has been the topic of several research reports. UBS Group lowered their price target on shares of Kenvue from $23.00 to $17.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 8th. Bank of America lowered their target price on shares of Kenvue from $25.00 to $21.00 and set a “buy” rating on the stock in a report on Wednesday, October 8th. Evercore ISI set a $18.00 target price on Kenvue in a research report on Tuesday, October 28th. The Goldman Sachs Group reduced their price target on Kenvue from $22.00 to $19.00 and set a “neutral” rating for the company in a research report on Thursday, October 2nd. Finally, Rothschild Redb upgraded Kenvue from a “hold” rating to a “strong-buy” rating in a research note on Friday, September 26th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and twelve have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $20.23.

Get Our Latest Analysis on Kenvue

About Kenvue

(Free Report)

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Featured Stories

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).